Historical Medical Device Changes from NMPA (CFDA) Announced Today

CFDA Cracking Down on Labeling—36% Defects Have Labelling Issues
June 25, 2018
Illustration of a laptop computer showing Grace Fu Palma speaking during a presentation for a webinar
Grace Palma, CEO of China Med Device, is interviewed by RAPS on China Medical Device Amendment
June 27, 2018

Historical Medical Device Changes from NMPA (CFDA) Announced Today

The last time the NMPA (CFDA) “Medical Device Supervision and Management Regulations” were completely overhauled was in 2014 with a supplemental update in 2017. Today (June 25th, 2018) the new draft regulations are going through historical changes focusing on expediting innovation and achieving much needed reform.  It is timely in that U.S. tariffs are anticipated to be levied at 25% duty on many of the medical devices shipped from China to the U.S.

Articles impacted: 12 articles newly added, 2 deleted and 39 modified.

Major changes:

  1. Perfecting medical device registration holder system. The registration holder can now be independent of the manufacturer.
  2. Relaxed the requirements for CER and clinical trials and acceptance of overseas clinical trial data. Streamline Innovation Approval and Priority Review to expedite certain devices entry.
  3. Exempted the requirement of home-country-approval for imported devices.
  4. Class II domestic devices approval has been moved from provincial SDA (CFDA) to the national one. Provincial and local SDA (CFDA) will establish career inspectors like the regional FDA inspectors in the U.S.
  5. Type testing and 3rd party reviews are being encouraged.

 

Please email info@ChinaMedDevice.com if you would like to schedule a consultation about these transformational changes from the NMPA (CFDA).

 

About China Med Device, LLC

China Med Device, LLC (https://ChinaMedDevice.com) provides turn-key solutions for western medical device/IVD companies to enter China with regulation and commercialization services. Our CFDA regulatory services cover strategy, RA, clinical evaluation, CRO, QA and post market compliance. We are experienced in handling innovation approvals and priority reviews. Our commercial services cover market assessment research, reimbursement, partnership, distribution qualification and management. We have offices in Beijing, Suzhou and Boston. Our management team has 100+ years of combined experience in medical device and IVD and has been involved with 1,000+ CFDA certificates and 250+ companies’ success.